{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:54:02Z","timestamp":1792403642467,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.tmrv.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T03:11:25Z","timestamp":1550113885000},"page":"98-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"33","author":[{"given":"Emma J.M.","family":"Grigor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Montroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Presseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-382X","authenticated-orcid":false,"given":"Manoj M.","family":"Lalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tmrv.2019.01.005_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br J Haematol"},{"issue":"9967","key":"10.1016\/j.tmrv.2019.01.005_bb0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"224","key":"10.1016\/j.tmrv.2019.01.005_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.tmrv.2019.01.005_bb0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.tmrv.2019.01.005_bb0035","series-title":"Juno pulls the plug on a once-promising cancer treatment","author":"Garde","year":"2017"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.tmrv.2019.01.005_bb0045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"issue":"12","key":"10.1016\/j.tmrv.2019.01.005_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019321","article-title":"Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis","volume":"7","author":"Grigor","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.tmrv.2019.01.005_bb0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.tmrv.2019.01.005_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jclinepi.2015.07.010","article-title":"A principal component analysis is conducted for a case series quality appraisal checklist","volume":"69","author":"Guo","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.tmrv.2019.01.005_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jrsm.38","article-title":"Review: Cochrane handbook for systematic reviews for interventions, version 5.1.0, published 3\/2011. Julian P.T. Higgins and Sally green, editors","volume":"2","author":"Shuster","year":"2011","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.tmrv.2019.01.005_bb0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jclinepi.2014.03.003","article-title":"In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias","volume":"67","author":"Hunter","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"10.1016\/j.tmrv.2019.01.005_bb0075","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.tmrv.2019.01.005_bb0080","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tmrv.2019.01.005_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11427-016-5035-4","article-title":"An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"20","key":"10.1016\/j.tmrv.2019.01.005_bb0090","first-page":"4099","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize Brief report Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells","volume":"116","author":"Kochenderfer","year":"2010"},{"issue":"10","key":"10.1016\/j.tmrv.2019.01.005_bb0095","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.tmrv.2019.01.005_bb0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cgt.2014.50","article-title":"Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases","volume":"21","author":"Saied","year":"2014","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"10.1016\/j.tmrv.2019.01.005_bb0105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.tmrv.2019.01.005_bb0115","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.tmrv.2019.01.005_bb0120","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tmrv.2019.01.005_bb0125","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"95","key":"10.1016\/j.tmrv.2019.01.005_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.tmrv.2019.01.005_bb0135","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.tmrv.2019.01.005_bb0140","first-page":"3940","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2015"},{"issue":"12","key":"10.1016\/j.tmrv.2019.01.005_bb0145","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B\u00adcell depletion and remissions of malignancy along with cytokine\u00ad associated toxicity in a clinical trial of anti\u00adCD19 chimeric\u00adantigen\u00ad receptor\u2013transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"177","key":"10.1016\/j.tmrv.2019.01.005_bb0150","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.tmrv.2019.01.005_bb0155","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.tmrv.2019.01.005_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V122.21.151.151","article-title":"Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.tmrv.2019.01.005_bb0165","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.tmrv.2019.01.005_bb0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.tmrv.2019.01.005_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"OncoImmunology"},{"issue":"303","key":"10.1016\/j.tmrv.2019.01.005_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0185","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.tmrv.2019.01.005_bb0190","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-016-0357-z","article-title":"Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia","volume":"9","author":"Cai","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.tmrv.2019.01.005_bb0205","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"04","key":"10.1016\/j.tmrv.2019.01.005_bb0215","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1017\/S147895151600095X","article-title":"Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia","volume":"15","author":"Prudent","year":"2017","journal-title":"Palliat Support Care"},{"key":"10.1016\/j.tmrv.2019.01.005_bb0220","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"6","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"355","key":"10.1016\/j.tmrv.2019.01.005_bb0225","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkins lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.tmrv.2019.01.005_bb0230","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory \u2013 derived CD19 CAR T \u2013 cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"51","key":"10.1016\/j.tmrv.2019.01.005_bb0235","doi-asserted-by":"crossref","first-page":"e5676","DOI":"10.1097\/MD.0000000000005676","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.tmrv.2019.01.005_bb0240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.tmrv.2019.01.005_bb0245","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.tmrv.2019.01.005_bb0255","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.tmrv.2019.01.005_bb0260","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.tmrv.2019.01.005_bb0265","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tmrv.2019.01.005_bb0270","article-title":"Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T cells","author":"Lai","year":"2017","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.tmrv.2019.01.005_bb0275","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tmrv.2019.01.005_bb0280","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"374","key":"10.1016\/j.tmrv.2019.01.005_bb0285","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.tmrv.2019.01.005_bb0290","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.tmrv.2019.01.005_bb0295","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.tmrv.2019.01.005_bb0300","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tmrv.2019.01.005_bb0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1188\/17.CJON.S2.29-34","article-title":"Cytokine release syndrome: inpatient Care for Side Effects of CAR T-cell therapy","volume":"21","author":"Smith","year":"2017","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10.1016\/j.tmrv.2019.01.005_bb0310","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.tmrv.2019.01.005_bb0315","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2217\/imt-2017-0070","article-title":"Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma","volume":"9","author":"Zahid","year":"2017","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.tmrv.2019.01.005_bb0320","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"15","key":"10.1016\/j.tmrv.2019.01.005_bb0325","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.tmrv.2019.01.005_bb0330","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.tmrv.2019.01.005_bb0335","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.tmrv.2019.01.005_bb0340","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tmrv.2019.01.005_bb0345","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"14","key":"10.1016\/j.tmrv.2019.01.005_bb0350","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate Cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.tmrv.2019.01.005_bb0355","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1042\/BST20160037","article-title":"Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview","volume":"44","author":"Lamers","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"10.1016\/j.tmrv.2019.01.005_bb0360","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0365","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.tmrv.2019.01.005_bb0370","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.tmrv.2019.01.005_bb0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"399","key":"10.1016\/j.tmrv.2019.01.005_bb0380","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.tmrv.2019.01.005_bb0385","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CJI.0000000000000160","article-title":"Possible compartmental cytokine release syndrome in a patient with recurrent ovarian Cancer after treatment with Mesothelin-targeted CAR-T cells","volume":"40","author":"Tanyi","year":"2017","journal-title":"J Immunother"},{"issue":"12","key":"10.1016\/j.tmrv.2019.01.005_bb0390","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.tmrv.2019.01.005_bb0395","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.tmrv.2019.01.005_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","article-title":"A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy","volume":"10","author":"Zhang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.tmrv.2019.01.005_bb0405","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088779631830172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088779631830172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:05Z","timestamp":1760138345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088779631830172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S088779631830172X"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2019.01.005","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}